| human | Q5 |
| P691 | NL CR AUT ID | xx0065056 |
| P496 | ORCID iD | 0000-0002-2818-9808 |
| P1153 | Scopus author ID | 7006591993 |
| P214 | VIAF ID | 284624882 |
| P69 | educated at | Albert Einstein College of Medicine | Q2030894 |
| P108 | employer | Elizabeth Glaser Pediatric AIDS Foundation | Q16992396 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development | Q5409765 | ||
| P735 | given name | Lynne | Q19830569 |
| Lynne | Q19830569 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q100572208 | 'There are no more secrets': acceptability of a family-centered model of care for HIV positive children in Eswatini |
| Q47547085 | 24-month HIV-free survival among infants born to HIV-positive women enrolled in Option B+ program in Kigali, Rwanda: The Kabeho Study |
| Q57953673 | A Behavioral and Cognitive Profile of Clinically Stable HIV-Infected Children |
| Q38394472 | A multi-disciplinary approach to implementation science: the NIH-PEPFAR PMTCT implementation science alliance |
| Q38886823 | A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). |
| Q57953904 | A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection |
| Q42629119 | A trial of three antiretroviral regimens in HIV-1-infected children |
| Q36077016 | A trigger-based design for evaluating the safety of in utero antiretroviral exposure in uninfected children of human immunodeficiency virus-infected mothers |
| Q57953906 | ANTIRETROVIRAL THERAPY AND INTERRUPTION OF HIV PERINATAL TRANSMISSION |
| Q98612109 | Accelerating progress towards the elimination of mother-to-child transmission of HIV: a narrative review |
| Q47555154 | Achieving Viral Suppression in 90% of People Living with HIV on Antiretroviral Therapy in Low- and Middle-Income Countries: Progress, Challenges, and Opportunities |
| Q34711999 | Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero |
| Q37335159 | Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis |
| Q35629692 | Advances in the prevention of vertical transmission of human immunodeficiency virus |
| Q46347977 | Alternatives to HIV-1 RNA concentration and CD4 count to predict mortality in HIV-1-infected children in resource-poor settings |
| Q90600104 | Analysis of Pharmacovigilance Databases for Dolutegravir Safety in Pregnancy |
| Q35682303 | Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis |
| Q34608508 | Antibody maturation and viral diversification in HIV-infected women |
| Q45625702 | Antimicrobial-specific cell-mediated immune reconstitution in children with advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy |
| Q31158739 | Antiretroviral Prophylaxis to Reduce Breast Milk Transmission of HIV Type 1: New Data but Still Questions |
| Q57865684 | Antiretroviral Therapy and Adverse Pregnancy Outcome: The Elephant in the Room? |
| Q37878232 | Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children |
| Q37768599 | Antiretroviral drugs to prevent breastfeeding HIV transmission |
| Q34667936 | Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance |
| Q33959672 | Antiretroviral therapy during pregnancy and the risk of an adverse outcome |
| Q34494986 | Antiretroviral treatment for children with peripartum nevirapine exposure |
| Q35074791 | Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. |
| Q42333841 | Antiretrovirals in pregnancy: a note of caution |
| Q48094037 | Assessing Very Early Infant Diagnosis Turnaround Times: Findings from a Birth Testing Pilot in Lesotho. |
| Q91598950 | Association of Antiretroviral Drug Regimen With Viral Suppression in HIV-positive Children on Antiretroviral Therapy in Eswatini |
| Q46971460 | Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission |
| Q51575737 | Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission. |
| Q33788608 | Association of selected phenotypic markers of lymphocyte activation and differentiation with perinatal human immunodeficiency virus transmission and infant infection |
| Q35224956 | Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents |
| Q35647376 | Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338). |
| Q37558394 | Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention |
| Q57207477 | Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention |
| Q34745570 | Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication |
| Q38801873 | Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057. |
| Q46526973 | Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine |
| Q40732344 | Brief Report: APOL1 Renal Risk Variants Are Associated With Chronic Kidney Disease in Children and Youth With Perinatal HIV Infection |
| Q40196913 | Brief Report: Pediatric Cancer Burden and Treatment Resources Within the Pediatric IeDEA Consortium |
| Q57953864 | Can Perinatal HIV Infection Be Eliminated in the United States? |
| Q34881120 | Cardiac effects of in-utero exposure to antiretroviral therapy in HIV-uninfected children born to HIV-infected mothers |
| Q96292569 | Challenges in the Early Infant HIV Diagnosis and Treatment Cascade |
| Q38757697 | Challenges in the Elimination of Pediatric HIV-1 Infection |
| Q45753012 | Characteristics of acute pneumonia in human immunodeficiency virus-infected children and association with long term mortality risk. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group |
| Q101567926 | Characterizing and Managing Pediatric SARS-CoV-2 Infection. Learning about the Virus in a Global Classroom |
| Q44374368 | Children born into families affected by HIV. |
| Q36063383 | Chlamydia and Gonorrhea in HIV-Infected Pregnant Women and Infant HIV Transmission |
| Q37836433 | Chlamydia trachomatis and Neisseria gonorrhoeae in HIV-infected Pregnant Women and Adverse Infant Outcomes |
| Q100428732 | Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo |
| Q103835632 | Clinical manifestations, prevalence, risk factors, outcomes, transmission, diagnosis and treatment of COVID-19 in pregnancy and postpartum: a living systematic review protocol |
| Q98890158 | Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis |
| Q35840756 | Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants |
| Q36876216 | Cognitive function and neurodevelopmental outcomes in HIV-infected Children older than 1 year of age randomized to early versus deferred antiretroviral therapy: the PREDICT neurodevelopmental study |
| Q33958839 | Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission |
| Q36547343 | Combination antiretroviral use and preterm birth |
| Q45745660 | Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team |
| Q48303065 | Combined evaluation of sexually transmitted infections in HIV-infected pregnant women and infant HIV transmission |
| Q104136768 | Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis |
| Q44157151 | Concentrations of protease inhibitors in cord blood after in utero exposure |
| Q54257908 | Congenital CMV and HIV Perinatal Transmission. |
| Q42706790 | Conventional early infant diagnosis in Lesotho from specimen collection to results usage to manage patients: Where are the bottlenecks? |
| Q44384674 | Cotrimoxazole prophylaxis in HIV-infected pregnant women: only a first step |
| Q46584742 | Creating Sustainable Collaborations for Implementation Science: The Case of the NIH-PEPFAR PMTCT Implementation Science Alliance |
| Q42600626 | Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus-infected children. The National Institute of Child Health and Hum |
| Q40261944 | Cytomegalovirus Urinary Shedding in HIV-infected Pregnant Women and Congenital Cytomegalovirus Infection |
| Q92751481 | Decision Making in a Time of Uncertainty: Dolutegravir for Reproductive-Age Women |
| Q33572442 | Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era |
| Q98231948 | Defining gaps in pre-exposure prophylaxis delivery for pregnant and post-partum women in high-burden settings using an implementation science framework |
| Q33668265 | Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. TUBE Meeting Workshop Attendees. Technology Utilization for HIV-1 Blood Evaluation and Standardization in Pediatrics |
| Q44074406 | Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group prot |
| Q54536404 | Diagnosis of HIV Infection During Early Infancy: How Early Is Early Enough? |
| Q35996827 | Early Combination Antiretroviral Therapy Limits Exposure to HIV-1 Replication and Cell-Associated HIV-1 DNA Levels in Infants |
| Q37111670 | Early antiretroviral therapy of HIV-infected infants in resource-limited countries: possible, feasible, effective and challenging |
| Q51950647 | Early neurodevelopmental markers predictive of mortality in infants infected with HIV-1. |
| Q36521955 | Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial |
| Q86645966 | Editorial commentary: New challenges in the elimination of pediatric HIV infection: the expanding population of HIV-exposed but uninfected children |
| Q44751353 | Efavirenz reclassified as FDA pregnancy category D. |
| Q57953696 | Effect of Perinatal Antiretroviral Drug Exposure on Hematologic Values in HIV‐Uninfected Children: An Analysis of the Women and Infants Transmission Study |
| Q104610402 | Effect of SARS-CoV-2 Infection in Pregnancy on Maternal and Neonatal Outcomes in Africa: An AFREhealth Call for Evidence through Multicountry Research Collaboration |
| Q53942007 | Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. |
| Q44029770 | Effect of intravenous immunoglobulin (IVIG) on CD4+ lymphocyte decline in HIV-infected children in a clinical trial of IVIG infection prophylaxis. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial |
| Q57953707 | Effects of Polymorphisms of Chemokine Receptors on Neurodevelopment and the Onset of Encephalopathy in Children with Perinatal HIV-1 Infection |
| Q35452458 | Effects of cessation of breastfeeding in HIV-1-exposed, uninfected children in Malawi |
| Q34634644 | Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial |
| Q34657178 | Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial |
| Q45751388 | Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. |
| Q73588241 | Elevated CD8+DR+ lymphocytes in HIV-exposed infants with early positive HIV cultures: a possible early marker of intrauterine transmission. Women and Infants Transmission Study Group |
| Q92489546 | Emerging evidence from a systematic review of safety of pre-exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading? |
| Q104142237 | Enhanced and timely investigation of ARVs for use in pregnant women |
| Q36440580 | Estimates of peripartum and postnatal mother-to-child transmission probabilities of HIV for use in Spectrum and other population-based models |
| Q58778724 | Estimating the cost of diagnosing HIV at birth in Lesotho |
| Q37360783 | Evaluation and management of the infant exposed to HIV-1 in the United States |
| Q45763456 | Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team |
| Q27690864 | Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. |
| Q35989706 | Evaluation of viral load thresholds for predicting new World Health Organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy |
| Q46558677 | Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission |
| Q57953505 | Faculty of 1000 evaluation for Changing Trends in Complications and Mortality among US Youth and Young Adults with HIV Infection in the Era of Combination Antiretroviral Therapy |
| Q57953494 | Faculty of 1000 evaluation for Feasibility of Routinely Offering Early Combined Antiretroviral Therapy to HIV-Infected Infants in a Resource-Limited Country: The ANRS-Pediacam Study in Cameroon |
| Q57953527 | Faculty of 1000 evaluation for Hepatotoxicity in Children Receiving Isoniazid Therapy for Latent Tuberculosis Infection |
| Q57953533 | Faculty of 1000 evaluation for Lower peak bone mass and abnormal trabecular and cortical microarchitecture in young men infected with HIV early in life |
| Q57953524 | Faculty of 1000 evaluation for Maternal immunization |
| Q57953514 | Faculty of 1000 evaluation for Missed Opportunities for Early Infant HIV Diagnosis: Results of a National Study in South Africa |
| Q57953497 | Faculty of 1000 evaluation for Outcomes of Infants Starting Antiretroviral Therapy in Southern Africa, 2004-2012 |
| Q57953519 | Faculty of 1000 evaluation for Pregnancy outcomes and birth defects from an antiretroviral drug safety study of women in South Africa and Zambia |
| Q57953510 | Faculty of 1000 evaluation for Pubertal development in HIV-infected African children on first-line antiretroviral therapy |
| Q57953502 | Faculty of 1000 evaluation for Severe Infections in HIV-Exposed Uninfected Infants Born in a European Country |
| Q35034306 | First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial |
| Q43257966 | Frequency of gastroenteritis and gastroenteritis-associated mortality with early weaning in HIV-1-uninfected children born to HIV-infected women in Malawi |
| Q42992271 | GB virus C infection in children with perinatal human immunodeficiency virus infection |
| Q37557650 | Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection |
| Q112280882 | Growth and CD4 patterns of adolescents living with perinatally acquired HIV worldwide, a CIPHER cohort collaboration analysis |
| Q42675238 | Growth in human immunodeficiency virus-infected children receiving ritonavir-containing antiretroviral therapy |
| Q33650105 | Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of Amer |
| Q34212799 | Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the |
| Q49617530 | HIV antiretroviral resistance and transmission in mother-infant pairs enrolled in a large perinatal study |
| Q28660329 | HIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmission |
| Q45569313 | Hepatitis C prevalence in children with perinatal human immunodeficiency virus infection enrolled in a long-term follow-up protocol |
| Q45740727 | Human immunodeficiency virus (HIV) type 1 antibodies in perinatal HIV-1 infection: association with human HIV-1 transmission, infection, and disease progression. For the Women and Infants Transmission Study |
| Q43779185 | Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine |
| Q45402822 | Human immunodeficiency virus, mycobacterium tuberculosis, and pregnancy: a deadly combination |
| Q38885782 | Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. |
| Q57953751 | Immune Reconstitution after Receipt of Highly Active Antiretroviral Therapy in Children with Advanced or Progressive HIV Disease and Complete or Partial Viral Load Responsea |
| Q44879671 | Immune parameters and morbidity in hard drug and human immunodeficiency virus-exposed but uninfected infants |
| Q40619254 | Immunologic targets of HIV infection: T cells. NICHD IVIG Clinical Trial Group, and the NHLBI P2C2 Pediatric Pulmonary and Cardiac Complications of HIV Infection Study Group. |
| Q43041554 | Impact of GB virus type C infection on mother-to-child HIV transmission in the Women and Infants Transmission Study Cohort |
| Q37304975 | Impact of maternal and infant antiretroviral drug regimens on drug resistance in HIV-infected breastfeeding infants |
| Q38744152 | Improving estimates of children living with HIV from the Spectrum AIDS Impact Model |
| Q36800856 | In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children |
| Q89029479 | In-utero ART exposure and the need for pharmacovigilance |
| Q35996783 | Infant outcomes after maternal antiretroviral exposure in resource-limited settings |
| Q54214490 | Infectious Morbidity, Mortality and Nutrition in HIV-Exposed, Uninfected, Formula Fed Infants: Results from the HPTN 040/PACTG 1043 Trial. |
| Q34756810 | Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants |
| Q36934060 | International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update |
| Q64093899 | Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial |
| Q38882753 | Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. |
| Q33873955 | Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial |
| Q52180229 | Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. |
| Q77391557 | Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine |
| Q33362020 | Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children |
| Q35163596 | Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A |
| Q35659264 | Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy |
| Q57953852 | Lymphoproliferative Responses to Recombinant HIV‐1 Envelope Antigens in Neonates and Infants Receiving gp120 Vaccines |
| Q36218701 | Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060. |
| Q36778390 | Male circumcision for prevention of HIV and other sexually transmitted diseases |
| Q95814388 | Manipulating the immune system with immune globulin. The National Institute of Child Health and Human Development. Intravenous Immunoglobulin Study Group |
| Q57953959 | Maternal Drug Use in Perinatal HIV Studies: The Women and Infants Transmission Study |
| Q36581681 | Maternal Highly Active Antiretroviral Therapy and Child HIV-Free Survival in Malawi, 2004-2009. |
| Q44398943 | Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. |
| Q46346962 | Maternal viral load and rate of disease progression among vertically HIV-1-infected children: an international meta-analysis |
| Q98458342 | More on Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China |
| Q35171059 | Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life |
| Q34181048 | Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants |
| Q43708324 | Nevirapine concentrations in newborns receiving an extended prophylactic regimen |
| Q36238419 | Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children |
| Q38853723 | Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial. |
| Q59692402 | Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team |
| Q91822464 | Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects |
| Q45732701 | Osteonecrosis of the hip (Legg-Calvé-Perthes disease) in human immunodeficiency virus-infected children |
| Q36565583 | Outcomes of antiretroviral therapy in children in Asia and Africa: a comparative analysis of the IeDEA pediatric multiregional collaboration |
| Q45739850 | Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children |
| Q44681462 | Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection |
| Q57953857 | Perinatal Exposure to Zidovudine — Benefits and Risks |
| Q45122582 | Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. |
| Q33765130 | Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial |
| Q35636071 | Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women |
| Q33705707 | Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. |
| Q35598502 | Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants |
| Q45155108 | Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. |
| Q37551251 | Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life |
| Q44273565 | Pharmacokinetics and tolerance of zidovudine in preterm infants |
| Q57787270 | Pharmacokinetics of Increased Nelfinavir Plasma Concentrations in Women During Pregnancy and Postpartum |
| Q36084313 | Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women |
| Q33977967 | Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children |
| Q43816550 | Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants |
| Q57953657 | Pharmacokinetics of oral zidovudine administered during labour: a preliminary study |
| Q35547832 | Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women |
| Q43822045 | Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women |
| Q50055422 | Piloting very early infant diagnosis of HIV in Lesotho: Acceptability and feasibility among mothers, health workers and laboratory personnel. |
| Q40826530 | Planning for children whose parents are dying of HIV/AIDS. American Academy of Pediatrics. Committee on Pediatric AIDS, 1998-1999. |
| Q35622844 | Point-of-care capillary blood lactate measurements in human immunodeficiency virus-uninfected children with in utero exposure to human immunodeficiency virus and antiretroviral medications |
| Q30569674 | Pooled individual data analysis of 5 randomized trials of infant nevirapine prophylaxis to prevent breast-milk HIV-1 transmission |
| Q44208352 | Postexposure prophylaxis of breastfeeding HIV-exposed infants with antiretroviral drugs to age 14 weeks: updated efficacy results of the PEPI-Malawi trial |
| Q43260833 | Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy |
| Q57207516 | Postnatal Human Immunodeficiency Virus-1 Transmission After Cessation of Infant Extended Antiretroviral Prophylaxis and Effect of Maternal Highly Active Antiretroviral Therapy |
| Q35620778 | Potential confounding of the association between exposure to nucleoside analogues and mitochondrial dysfunction in HIV-uninfected and indeterminate infants |
| Q53734332 | Preconception ART and preterm birth: real effect or selection bias? - Authors' reply. |
| Q34200009 | Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission |
| Q44470467 | Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose |
| Q40119999 | Preventing Human Immunodeficiency Virus Acquisition in Youth-Generations at Risk |
| Q37732300 | Prevention in neglected subpopulations: prevention of mother-to-child transmission of HIV infection |
| Q57953625 | Prevention of Breast Milk Transmission of HIV: The Time Is Now |
| Q48569593 | Prevention of Hiv-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in Hiv-1-Infected Women with High Cd4 Cell Count (Impaact Promise): A R |
| Q57953595 | Prevention of Mother-to-Child HIV-1 Transmission—Why We Still Need a Preventive HIV Immunization Strategy |
| Q57953639 | Prevention of Mother-to-Child Transmission of HIV-1 |
| Q51870305 | Prevention of mother-to-child HIV transmission: can we meet the goal of global elimination of new pediatric infections? |
| Q38867303 | Programmatic impact of the evolution of WHO pediatric antiretroviral treatment guidelines for resource-limited countries (Tukula Fenna Project, Uganda). |
| Q44988662 | Progress in prevention of perinatal HIV-1. |
| Q38026485 | Progress, challenges, and new opportunities for the prevention of mother-to-child transmission of HIV under the US President's Emergency Plan for AIDS Relief |
| Q57953811 | Progression of HIV Disease Among Women Following Delivery |
| Q57953944 | Prophylactic Immune Globulin in Children with HIV Disease |
| Q58427341 | Prophylactic Intravenous Immunoglobulin in HIV-Infected Children With CD4+ Counts of 0.20×109/L or More |
| Q67518325 | Prophylactic intravenous immunoglobulin in HIV-infected children with CD4+ counts of 0.20 x 10(9)/L or more. Effect on viral, opportunistic, and bacterial infections. The National Institute of Child Health and Human Development Intravenous Immunoglo |
| Q57953612 | Protecting the Next Generation — Eliminating Perinatal HIV-1 Infection |
| Q40400569 | Protecting the health of our AIDS-free generation: beyond prevention of mother-to-child HIV transmission |
| Q45741770 | Quantification of human immunodeficiency virus type 1 p24 antigen and antibody rivals human immunodeficiency virus type 1 RNA and CD4+ enumeration for prognosis. National Institute of Child Health and Human Development Intravenous Immunoglobulin Cli |
| Q57953916 | RIFABUTIN |
| Q34339266 | Raltegravir pharmacokinetics in neonates following maternal dosing |
| Q33657188 | Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ≥ 400 cells/mm3. |
| Q46214532 | Realization of an AIDS-free generation: ensuring sustainable treatment for children |
| Q47560045 | Recent progress in immune-based interventions to prevent HIV-1 transmission to children |
| Q45400366 | Recommendations for human immunodeficiency virus screening, prophylaxis, and treatment for pregnant women in the United States |
| Q37742040 | Reducing CD4 Monitoring in Children on Antiretroviral Therapy With Virologic Suppression |
| Q53068712 | Reply to Kojima and Klausner. |
| Q57953813 | Risk factors for Kaposi's sarcoma-associated herpesvirus infection among HIV-1-infected pregnant women in the USA |
| Q54688594 | Risk factors for in utero and intrapartum transmission of HIV. |
| Q45748047 | Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. |
| Q47232710 | Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. Pediatric AIDS Clinical Trials Group 185 Team |
| Q87966691 | Risk of HIV Acquisition During Pregnancy and Postpartum: A Call for Action |
| Q97549165 | SARS-COV-2 Maternal-Child Transmission: Can It Occur Before Delivery and How Do We Prove It? |
| Q45730859 | Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children |
| Q44088125 | Safety and effectiveness of efavirenz versus nevirapine-based regimens in resource-limited settings: evidence, clinical practice and modelling projections |
| Q45762210 | Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group |
| Q46500082 | Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life. |
| Q42614813 | Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months |
| Q32068631 | Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women |
| Q38909409 | Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis |
| Q34667930 | Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants |
| Q35090697 | Safety of cotrimoxazole in pregnancy: a systematic review and meta-analysis |
| Q34116017 | Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts |
| Q34216455 | Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis |
| Q34420923 | Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. |
| Q28538275 | Safety of pediatric HIV elimination: the growing population of HIV- and antiretroviral-exposed but uninfected infants |
| Q36333957 | Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants |
| Q95729801 | Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants |
| Q46356798 | Serum HIV-1 p24 antibody, HIV-1 RNA copy number and CD4 lymphocyte percentage are independently associated with risk of mortality in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinica |
| Q45751038 | Serum vitamin A concentrations in a North American cohort of human immunodeficiency virus type 1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group |
| Q57953900 | Short-course zidovudine for prevention of perinatal infection |
| Q45771659 | Sinusitis in children infected with human immunodeficiency virus: clinical characteristics, risk factors, and prophylaxis. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group |
| Q36113222 | Stavudine concentrations in women receiving postpartum antiretroviral treatment and their breastfeeding infants |
| Q43882621 | Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection |
| Q57953790 | Successes and Challenges in the Perinatal HIV-1 Epidemic in the United States as Illustrated by the HIV-1 Serosurvey of Childbearing Women |
| Q57953948 | Summary of the Workshop on Passive Immunotherapy in the Prevention and Treatment of HIV Infection |
| Q35156725 | Syphilis in HIV-infected mothers and infants: results from the NICHD/HPTN 040 study |
| Q45729069 | Tale of two epidemics--the continuing challenge of preventing mother-to-child transmission of human immunodeficiency virus |
| Q36146022 | Tenofovir Pre-exposure Prophylaxis for Pregnant and Breastfeeding Women at Risk of HIV Infection: The Time is Now. |
| Q39004507 | Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding |
| Q37238911 | Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection |
| Q57953793 | The Impact of Race/Ethnicity on Mother-to-Child HIV Transmission in the United States in Pediatric AIDS Clinical Trials Group Protocol 316 |
| Q57953820 | The Interface of Perinatal HIV Prevention, Antiretroviral Drug Resistance, and Antiretroviral Treatment: What Do We Really Know? |
| Q36941673 | The challenges of success: adolescents with perinatal HIV infection |
| Q51365567 | The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis |
| Q99556728 | The evolving picture of SARS-CoV-2 and COVID-19 in children: critical knowledge gaps |
| Q45763459 | The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobuli |
| Q41057935 | The role of antiretroviral therapy in the management of HIV infection in women. |
| Q57953574 | Three Postpartum Antiretroviral Regimens to Prevent Intrapartum HIV Infection |
| Q36662110 | Three postpartum antiretroviral regimens to prevent intrapartum HIV infection |
| Q52728572 | Time to First-Line ART Failure and Time to Second-Line ART Switch in the IeDEA Pediatric Cohort. |
| Q39013558 | Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis |
| Q37290917 | Total lymphocyte count: not a surrogate marker for risk of death in HIV-infected Ugandan children. |
| Q36635719 | Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel |
| Q45749190 | Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus. ACTG 179 Study Team. AIDS Clinical Trials Group |
| Q81092549 | Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America |
| Q81285745 | Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America |
| Q37409196 | Treatment interruption after pregnancy: effects on disease progression and laboratory findings |
| Q35788768 | Tuberculosis in pediatric antiretroviral therapy programs in low- and middle-income countries: Diagnosis and screening practices |
| Q34719306 | Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial |
| Q35029438 | U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States |
| Q36781481 | Unresolved antiretroviral treatment management issues in HIV-infected children |
| Q91721510 | Updates to the Spectrum/AIM model for estimating key HIV indicators at national and subnational levels |
| Q45744567 | Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273). |
| Q56888618 | Using Observational Data to Inform HIV Policy Change for Children and Youth |
| Q44142380 | Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group |
| Q34683397 | Viral load predicts new world health organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy, independent of CD4 T lymphocyte value |
| Q35917564 | World Health Organization generic protocol to assess drug-resistant HIV among children <18 months of age and newly diagnosed with HIV in resource-limited countries |
| Q38664458 | Youth engagement in developing an implementation science research agenda on adolescent HIV testing and care linkages in sub-Saharan Africa |
Search more.